Prof.r. J. Coury

Biography

Robert J. Coury is the Chairman of Mylan N.V.  Under his visionary leadership, Mylan has transformed from the third largest generics pharmaceutical company in the U.S. into one of the largest pharmaceutical companies in the world, earning spots in both the S&P 500 and, prior to the company’s reincorporation outside of the U.S. in 2015, the Fortune 500.  Mr. Coury was first elected to Mylan’s board of directors in February 2002, having served since 1995 as a strategic advisor to the company.  He became the board’s vice chairman shortly after his election and served as CEO from September 2002 until January 2012, and as executive chairman from 2012 until he became chairman in June 2016. Since 2007, Mr. Coury has led the company through a series of transactions totaling more than $25 billion, which transformed Mylan into a global powerhouse within the highly competitive pharmaceutical industry, with more than 35,000 employees and products sold in over 165 countries.   In 2007, Mylan purchased India-based Matrix Laboratories, a major producer of active pharmaceutical ingredients, and the generics business of Europe-based Merck KGaA.  Subsequent acquisitions under Mr. Coury’s leadership further expanded the company into new therapeutic categories and greatly enhanced its geographic and commercial footprint.  In 2010, Mylan acquired Bioniche Pharma, a global injectables business in Ireland; in 2012, Mylan acquired India-based Agila Specialties, a global injectables company; and in 2015, Mylan acquired Abbott Laboratories’ non-U.S. developed markets specialty and branded generics business, and Famy Care’s women’s healthcare businesses.  Most recently, Mylan acquired Meda, a leading international specialty pharmaceutical company that sells both prescription and over-the-counter products.   

Research Interest

generics pharmaceutical and business